カテゴリ： 世界, 医療/バイオ, QYResearch

CAR T細胞療法の世界市場2023年：CD19-対象、BCMA-対象

■ 英語タイトル：Global CAR T-Cell Therapy Market Research Report 2023

調査会社QYResearch社が発行したリサーチレポート（データ管理コード：QYR23MA8710）■ 発行会社/調査会社：QYResearch
■ 商品コード：QYR23MA8710
■ 発行日：2023年3月
■ 調査対象地域：グローバル
■ 産業分野：医薬品
■ ページ数：92
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（受注後2-3営業日）
■ 販売価格オプション（消費税別）
Single User（1名様閲覧用）USD2,900 ⇒換算￥440,800見積依頼/購入/質問フォーム
Multi User（5名様閲覧用）USD4,350 ⇒換算￥661,200見積依頼/購入/質問フォーム
Enterprise License（同一法人内共有可）USD5,800 ⇒換算￥881,600見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※QYResearch社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[CAR T細胞療法の世界市場2023年：CD19-対象、BCMA-対象]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

当調査資料はCAR T細胞療法のグローバル市場について調査・分析し、世界のCAR T細胞療法市場概要、市場トレンド、主要企業別競争状況、タイプ別セグメント分析（CD19-対象、BCMA-対象）、用途別セグメント分析（リンパ腫、多発性骨髄腫）、地域別市場規模、主要企業のプロファイルなどに関する情報を掲載しています。主要企業としては、Novartis、Gilead Sciences、Bristol-Myers Squibb、J & J、JW Therapeutics、FOSUNKite、CARsgen Therapeutics (Pipeline)、Autolus Therapeutics(Pipeline)、Sorrento Therapeutics(Pipeline)、Mustang Bio(Pipeline)、Bluebird Bio(Pipeline)、Cellectis(Pipeline)、Allogene Therapeutics(Pipeline)、Celyad(Pipeline)などが含まれています。CAR T細胞療法のグローバル市場は、2022年にXXX米ドル、2029年にはXXX米ドルに達すると予測され、予測期間の年平均成長率はXXX％です。新型コロナとロシア・ウクライナ戦争の影響は、CAR T細胞療法市場規模を算出する際に考慮しました。

・CAR T細胞療法市場の概要
- CAR T細胞療法の種類別セグメント
- 世界のCAR T細胞療法市場規模：タイプ別分析（CD19-対象、BCMA-対象）
- CAR T細胞療法の用途別セグメント
- 世界のCAR T細胞療法市場規模：用途別分析（リンパ腫、多発性骨髄腫）
- 世界のCAR T細胞療法市場規模予測（2018年-2029年）

・CAR T細胞療法市場の成長トレンド
- CAR T細胞療法の地域別市場規模（2018年-2029年）
- CAR T細胞療法市場ダイナミクス
- CAR T細胞療法の業界動向
- CAR T細胞療法市場の成長ドライバ、課題、阻害要因

・主要企業別競争状況
- 企業別市場シェア
- 世界の主要企業、業界ランキング分析
- 市場への参入、M＆A動向

・種類別セグメント：CD19-対象、BCMA-対象
- 世界のCAR T細胞療法のタイプ別市場規模（2018年-2023年）
- 世界のCAR T細胞療法のタイプ別市場規模（2024年-2029年）

・用途別セグメント：リンパ腫、多発性骨髄腫
- 世界のCAR T細胞療法の用途別市場規模（2018年-2023年）
- 世界のCAR T細胞療法の用途別市場規模（2024年-2029年）

・CAR T細胞療法の地域別市場規模
- 北米のCAR T細胞療法市場規模（2018年-2029年）
- 米国のCAR T細胞療法市場規模（2018年-2029年）
- ヨーロッパのCAR T細胞療法市場規模（2018年-2029年）
- アジア太平洋のCAR T細胞療法市場規模（2018年-2029年）
- 中国のCAR T細胞療法市場規模（2018年-2029年）
- 日本のCAR T細胞療法市場規模（2018年-2029年）
- 韓国のCAR T細胞療法市場規模（2018年-2029年）
- インドのCAR T細胞療法市場規模（2018年-2029年）
- オーストラリアのCAR T細胞療法市場規模（2018年-2029年）
- 中南米のCAR T細胞療法市場規模（2018年-2029年）
- 中東・アフリカのCAR T細胞療法市場規模（2018年-2029年）

・主要企業のプロファイル：企業情報、事業概要、売上、動向
Novartis、Gilead Sciences、Bristol-Myers Squibb、J & J、JW Therapeutics、FOSUNKite、CARsgen Therapeutics (Pipeline)、Autolus Therapeutics(Pipeline)、Sorrento Therapeutics(Pipeline)、Mustang Bio(Pipeline)、Bluebird Bio(Pipeline)、Cellectis(Pipeline)、Allogene Therapeutics(Pipeline)、Celyad(Pipeline)

・アナリストの観点/結論

・調査手法と情報源

Chimeric antigen receptor (CAR) T-cell therapy is a way to get immune cells called T cells (a type of white blood cell) to fight cancer by changing them in the lab so they can find and destroy cancer cells. CAR T-cell therapy is also sometimes talked about as a type of cell-based gene therapy, because it involves altering the genes inside T cells to help them attack the cancer.
Highlights
The global CAR T-Cell Therapy market was valued at US$ 2805.8 million in 2022 and is anticipated to reach US$ 13510 million by 2029, witnessing a CAGR of 29.9% during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The global top three CAR T-Cell therapy players include Novartis, Gilead Sciences, Bristol-Myers Squibb, with a total market share of more than 99%. The largest player is Gilead Sciences, with a market share of over 50%. North America is the global most important consumer market for CAR T-Cell therapy, with a market share of more than 65%. In terms of type, CD19-targeted CAR cell therapy has a market share of over 90%. In the field of application, the market share of lymphoma exceeds 90%.
Report Scope
This report aims to provide a comprehensive presentation of the global market for CAR T-Cell Therapy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding CAR T-Cell Therapy.
The CAR T-Cell Therapy market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global CAR T-Cell Therapy market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the CAR T-Cell Therapy companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Novartis
Gilead Sciences
Bristol-Myers Squibb
J & J
JW Therapeutics
FOSUNKite
CARsgen Therapeutics (Pipeline)
Autolus Therapeutics(Pipeline)
Sorrento Therapeutics(Pipeline)
Mustang Bio(Pipeline)
Bluebird Bio(Pipeline)
Cellectis(Pipeline)
Allogene Therapeutics(Pipeline)
Celyad(Pipeline)
Segment by Type
CD19 – Targeted
BCMA – Targeted
Segment by Application
Lymphoma
Multiple Myeloma
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of CAR T-Cell Therapy companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

*** レポート目次（コンテンツ）***

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global CAR T-Cell Therapy Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 CD19 – Targeted
1.2.3 BCMA – Targeted
1.3 Market by Application
1.3.1 Global CAR T-Cell Therapy Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Lymphoma
1.3.3 Multiple Myeloma
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global CAR T-Cell Therapy Market Perspective (2018-2029)
2.2 CAR T-Cell Therapy Growth Trends by Region
2.2.1 Global CAR T-Cell Therapy Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 CAR T-Cell Therapy Historic Market Size by Region (2018-2023)
2.2.3 CAR T-Cell Therapy Forecasted Market Size by Region (2024-2029)
2.3 CAR T-Cell Therapy Market Dynamics
2.3.1 CAR T-Cell Therapy Industry Trends
2.3.2 CAR T-Cell Therapy Market Drivers
2.3.3 CAR T-Cell Therapy Market Challenges
2.3.4 CAR T-Cell Therapy Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top CAR T-Cell Therapy Players by Revenue
3.1.1 Global Top CAR T-Cell Therapy Players by Revenue (2018-2023)
3.1.2 Global CAR T-Cell Therapy Revenue Market Share by Players (2018-2023)
3.2 Global CAR T-Cell Therapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by CAR T-Cell Therapy Revenue
3.4 Global CAR T-Cell Therapy Market Concentration Ratio
3.4.1 Global CAR T-Cell Therapy Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by CAR T-Cell Therapy Revenue in 2022
3.5 CAR T-Cell Therapy Key Players Head office and Area Served
3.6 Key Players CAR T-Cell Therapy Product Solution and Service
3.7 Date of Enter into CAR T-Cell Therapy Market
3.8 Mergers & Acquisitions, Expansion Plans
4 CAR T-Cell Therapy Breakdown Data by Type
4.1 Global CAR T-Cell Therapy Historic Market Size by Type (2018-2023)
4.2 Global CAR T-Cell Therapy Forecasted Market Size by Type (2024-2029)
5 CAR T-Cell Therapy Breakdown Data by Application
5.1 Global CAR T-Cell Therapy Historic Market Size by Application (2018-2023)
5.2 Global CAR T-Cell Therapy Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America CAR T-Cell Therapy Market Size (2018-2029)
6.2 North America CAR T-Cell Therapy Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America CAR T-Cell Therapy Market Size by Country (2018-2023)
6.4 North America CAR T-Cell Therapy Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe CAR T-Cell Therapy Market Size (2018-2029)
7.2 Europe CAR T-Cell Therapy Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe CAR T-Cell Therapy Market Size by Country (2018-2023)
7.4 Europe CAR T-Cell Therapy Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific CAR T-Cell Therapy Market Size (2018-2029)
8.2 Asia-Pacific CAR T-Cell Therapy Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific CAR T-Cell Therapy Market Size by Region (2018-2023)
8.4 Asia-Pacific CAR T-Cell Therapy Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America CAR T-Cell Therapy Market Size (2018-2029)
9.2 Latin America CAR T-Cell Therapy Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America CAR T-Cell Therapy Market Size by Country (2018-2023)
9.4 Latin America CAR T-Cell Therapy Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa CAR T-Cell Therapy Market Size (2018-2029)
10.2 Middle East & Africa CAR T-Cell Therapy Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa CAR T-Cell Therapy Market Size by Country (2018-2023)
10.4 Middle East & Africa CAR T-Cell Therapy Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Novartis
11.1.1 Novartis Company Detail
11.1.2 Novartis Business Overview
11.1.3 Novartis CAR T-Cell Therapy Introduction
11.1.4 Novartis Revenue in CAR T-Cell Therapy Business (2018-2023)
11.1.5 Novartis Recent Development
11.2 Gilead Sciences
11.2.1 Gilead Sciences Company Detail
11.2.2 Gilead Sciences Business Overview
11.2.3 Gilead Sciences CAR T-Cell Therapy Introduction
11.2.4 Gilead Sciences Revenue in CAR T-Cell Therapy Business (2018-2023)
11.2.5 Gilead Sciences Recent Development
11.3 Bristol-Myers Squibb
11.3.1 Bristol-Myers Squibb Company Detail
11.3.2 Bristol-Myers Squibb Business Overview
11.3.3 Bristol-Myers Squibb CAR T-Cell Therapy Introduction
11.3.4 Bristol-Myers Squibb Revenue in CAR T-Cell Therapy Business (2018-2023)
11.3.5 Bristol-Myers Squibb Recent Development
11.4 J & J
11.4.1 J & J Company Detail
11.4.2 J & J Business Overview
11.4.3 J & J CAR T-Cell Therapy Introduction
11.4.4 J & J Revenue in CAR T-Cell Therapy Business (2018-2023)
11.4.5 J & J Recent Development
11.5 JW Therapeutics
11.5.1 JW Therapeutics Company Detail
11.5.2 JW Therapeutics Business Overview
11.5.3 JW Therapeutics CAR T-Cell Therapy Introduction
11.5.4 JW Therapeutics Revenue in CAR T-Cell Therapy Business (2018-2023)
11.5.5 JW Therapeutics Recent Development
11.6 FOSUNKite
11.6.1 FOSUNKite Company Detail
11.6.2 FOSUNKite Business Overview
11.6.3 FOSUNKite CAR T-Cell Therapy Introduction
11.6.4 FOSUNKite Revenue in CAR T-Cell Therapy Business (2018-2023)
11.6.5 FOSUNKite Recent Development
11.7 CARsgen Therapeutics (Pipeline)
11.7.1 CARsgen Therapeutics (Pipeline) Company Detail
11.7.2 CARsgen Therapeutics (Pipeline) Business Overview
11.7.3 CARsgen Therapeutics (Pipeline) CAR T-Cell Therapy Introduction
11.7.4 CARsgen Therapeutics (Pipeline) Revenue in CAR T-Cell Therapy Business (2018-2023)
11.7.5 CARsgen Therapeutics (Pipeline) Recent Development
11.8 Autolus Therapeutics(Pipeline)
11.8.1 Autolus Therapeutics(Pipeline) Company Detail
11.8.2 Autolus Therapeutics(Pipeline) Business Overview
11.8.3 Autolus Therapeutics(Pipeline) CAR T-Cell Therapy Introduction
11.8.4 Autolus Therapeutics(Pipeline) Revenue in CAR T-Cell Therapy Business (2018-2023)
11.8.5 Autolus Therapeutics(Pipeline) Recent Development
11.9 Sorrento Therapeutics(Pipeline)
11.9.1 Sorrento Therapeutics(Pipeline) Company Detail
11.9.2 Sorrento Therapeutics(Pipeline) Business Overview
11.9.3 Sorrento Therapeutics(Pipeline) CAR T-Cell Therapy Introduction
11.9.4 Sorrento Therapeutics(Pipeline) Revenue in CAR T-Cell Therapy Business (2018-2023)
11.9.5 Sorrento Therapeutics(Pipeline) Recent Development
11.10 Mustang Bio(Pipeline)
11.10.1 Mustang Bio(Pipeline) Company Detail
11.10.2 Mustang Bio(Pipeline) Business Overview
11.10.3 Mustang Bio(Pipeline) CAR T-Cell Therapy Introduction
11.10.4 Mustang Bio(Pipeline) Revenue in CAR T-Cell Therapy Business (2018-2023)
11.10.5 Mustang Bio(Pipeline) Recent Development
11.11 Bluebird Bio(Pipeline)
11.11.1 Bluebird Bio(Pipeline) Company Detail
11.11.2 Bluebird Bio(Pipeline) Business Overview
11.11.3 Bluebird Bio(Pipeline) CAR T-Cell Therapy Introduction
11.11.4 Bluebird Bio(Pipeline) Revenue in CAR T-Cell Therapy Business (2018-2023)
11.11.5 Bluebird Bio(Pipeline) Recent Development
11.12 Cellectis(Pipeline)
11.12.1 Cellectis(Pipeline) Company Detail
11.12.2 Cellectis(Pipeline) Business Overview
11.12.3 Cellectis(Pipeline) CAR T-Cell Therapy Introduction
11.12.4 Cellectis(Pipeline) Revenue in CAR T-Cell Therapy Business (2018-2023)
11.12.5 Cellectis(Pipeline) Recent Development
11.13 Allogene Therapeutics(Pipeline)
11.13.1 Allogene Therapeutics(Pipeline) Company Detail
11.13.2 Allogene Therapeutics(Pipeline) Business Overview
11.13.3 Allogene Therapeutics(Pipeline) CAR T-Cell Therapy Introduction
11.13.4 Allogene Therapeutics(Pipeline) Revenue in CAR T-Cell Therapy Business (2018-2023)
11.13.5 Allogene Therapeutics(Pipeline) Recent Development
11.14 Celyad(Pipeline)
11.14.1 Celyad(Pipeline) Company Detail
11.14.2 Celyad(Pipeline) Business Overview
11.14.3 Celyad(Pipeline) CAR T-Cell Therapy Introduction
11.14.4 Celyad(Pipeline) Revenue in CAR T-Cell Therapy Business (2018-2023)
11.14.5 Celyad(Pipeline) Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global CAR T-Cell Therapy Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2029
Table 2. Key Players of CD19 - Targeted
Table 3. Key Players of BCMA - Targeted
Table 4. Global CAR T-Cell Therapy Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2029
Table 5. Global CAR T-Cell Therapy Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 6. Global CAR T-Cell Therapy Market Size by Region (2018-2023) & (US$ Million)
Table 7. Global CAR T-Cell Therapy Market Share by Region (2018-2023)
Table 8. Global CAR T-Cell Therapy Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 9. Global CAR T-Cell Therapy Market Share by Region (2024-2029)
Table 10. CAR T-Cell Therapy Market Trends
Table 11. CAR T-Cell Therapy Market Drivers
Table 12. CAR T-Cell Therapy Market Challenges
Table 13. CAR T-Cell Therapy Market Restraints
Table 14. Global CAR T-Cell Therapy Revenue by Players (2018-2023) & (US$ Million)
Table 15. Global CAR T-Cell Therapy Market Share by Players (2018-2023)
Table 16. Global Top CAR T-Cell Therapy Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in CAR T-Cell Therapy as of 2022)
Table 17. Ranking of Global Top CAR T-Cell Therapy Companies by Revenue (US$ Million) in 2022
Table 18. Global 5 Largest Players Market Share by CAR T-Cell Therapy Revenue (CR5 and HHI) & (2018-2023)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players CAR T-Cell Therapy Product Solution and Service
Table 21. Date of Enter into CAR T-Cell Therapy Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global CAR T-Cell Therapy Market Size by Type (2018-2023) & (US$ Million)
Table 24. Global CAR T-Cell Therapy Revenue Market Share by Type (2018-2023)
Table 25. Global CAR T-Cell Therapy Forecasted Market Size by Type (2024-2029) & (US$ Million)
Table 26. Global CAR T-Cell Therapy Revenue Market Share by Type (2024-2029)
Table 27. Global CAR T-Cell Therapy Market Size by Application (2018-2023) & (US$ Million)
Table 28. Global CAR T-Cell Therapy Revenue Market Share by Application (2018-2023)
Table 29. Global CAR T-Cell Therapy Forecasted Market Size by Application (2024-2029) & (US$ Million)
Table 30. Global CAR T-Cell Therapy Revenue Market Share by Application (2024-2029)
Table 31. North America CAR T-Cell Therapy Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 32. North America CAR T-Cell Therapy Market Size by Country (2018-2023) & (US$ Million)
Table 33. North America CAR T-Cell Therapy Market Size by Country (2024-2029) & (US$ Million)
Table 34. Europe CAR T-Cell Therapy Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 35. Europe CAR T-Cell Therapy Market Size by Country (2018-2023) & (US$ Million)
Table 36. Europe CAR T-Cell Therapy Market Size by Country (2024-2029) & (US$ Million)
Table 37. Asia-Pacific CAR T-Cell Therapy Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2029
Table 38. Asia-Pacific CAR T-Cell Therapy Market Size by Region (2018-2023) & (US$ Million)
Table 39. Asia-Pacific CAR T-Cell Therapy Market Size by Region (2024-2029) & (US$ Million)
Table 40. Latin America CAR T-Cell Therapy Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 41. Latin America CAR T-Cell Therapy Market Size by Country (2018-2023) & (US$ Million)
Table 42. Latin America CAR T-Cell Therapy Market Size by Country (2024-2029) & (US$ Million)
Table 43. Middle East & Africa CAR T-Cell Therapy Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 44. Middle East & Africa CAR T-Cell Therapy Market Size by Country (2018-2023) & (US$ Million)
Table 45. Middle East & Africa CAR T-Cell Therapy Market Size by Country (2024-2029) & (US$ Million)
Table 46. Novartis Company Detail
Table 47. Novartis Business Overview
Table 48. Novartis CAR T-Cell Therapy Product
Table 49. Novartis Revenue in CAR T-Cell Therapy Business (2018-2023) & (US$ Million)
Table 50. Novartis Recent Development
Table 51. Gilead Sciences Company Detail
Table 52. Gilead Sciences Business Overview
Table 53. Gilead Sciences CAR T-Cell Therapy Product
Table 54. Gilead Sciences Revenue in CAR T-Cell Therapy Business (2018-2023) & (US$ Million)
Table 55. Gilead Sciences Recent Development
Table 56. Bristol-Myers Squibb Company Detail
Table 57. Bristol-Myers Squibb Business Overview
Table 58. Bristol-Myers Squibb CAR T-Cell Therapy Product
Table 59. Bristol-Myers Squibb Revenue in CAR T-Cell Therapy Business (2018-2023) & (US$ Million)
Table 60. Bristol-Myers Squibb Recent Development
Table 61. J & J Company Detail
Table 62. J & J Business Overview
Table 63. J & J CAR T-Cell Therapy Product
Table 64. J & J Revenue in CAR T-Cell Therapy Business (2018-2023) & (US$ Million)
Table 65. J & J Recent Development
Table 66. JW Therapeutics Company Detail
Table 67. JW Therapeutics Business Overview
Table 68. JW Therapeutics CAR T-Cell Therapy Product
Table 69. JW Therapeutics Revenue in CAR T-Cell Therapy Business (2018-2023) & (US$ Million)
Table 70. JW Therapeutics Recent Development
Table 71. FOSUNKite Company Detail
Table 72. FOSUNKite Business Overview
Table 73. FOSUNKite CAR T-Cell Therapy Product
Table 74. FOSUNKite Revenue in CAR T-Cell Therapy Business (2018-2023) & (US$ Million)
Table 75. FOSUNKite Recent Development
Table 76. CARsgen Therapeutics (Pipeline) Company Detail
Table 77. CARsgen Therapeutics (Pipeline) Business Overview
Table 78. CARsgen Therapeutics (Pipeline) CAR T-Cell Therapy Product
Table 79. CARsgen Therapeutics (Pipeline) Revenue in CAR T-Cell Therapy Business (2018-2023) & (US$ Million)
Table 80. CARsgen Therapeutics (Pipeline) Recent Development
Table 81. Autolus Therapeutics(Pipeline) Company Detail
Table 82. Autolus Therapeutics(Pipeline) Business Overview
Table 83. Autolus Therapeutics(Pipeline) CAR T-Cell Therapy Product
Table 84. Autolus Therapeutics(Pipeline) Revenue in CAR T-Cell Therapy Business (2018-2023) & (US$ Million)
Table 85. Autolus Therapeutics(Pipeline) Recent Development
Table 86. Sorrento Therapeutics(Pipeline) Company Detail
Table 87. Sorrento Therapeutics(Pipeline) Business Overview
Table 88. Sorrento Therapeutics(Pipeline) CAR T-Cell Therapy Product
Table 89. Sorrento Therapeutics(Pipeline) Revenue in CAR T-Cell Therapy Business (2018-2023) & (US$ Million)
Table 90. Sorrento Therapeutics(Pipeline) Recent Development
Table 91. Mustang Bio(Pipeline) Company Detail
Table 92. Mustang Bio(Pipeline) Business Overview
Table 93. Mustang Bio(Pipeline) CAR T-Cell Therapy Product
Table 94. Mustang Bio(Pipeline) Revenue in CAR T-Cell Therapy Business (2018-2023) & (US$ Million)
Table 95. Mustang Bio(Pipeline) Recent Development
Table 96. Bluebird Bio(Pipeline) Company Detail
Table 97. Bluebird Bio(Pipeline) Business Overview
Table 98. Bluebird Bio(Pipeline) CAR T-Cell Therapy Product
Table 99. Bluebird Bio(Pipeline) Revenue in CAR T-Cell Therapy Business (2018-2023) & (US$ Million)
Table 100. Bluebird Bio(Pipeline) Recent Development
Table 101. Cellectis(Pipeline) Company Detail
Table 102. Cellectis(Pipeline) Business Overview
Table 103. Cellectis(Pipeline) CAR T-Cell Therapy Product
Table 104. Cellectis(Pipeline) Revenue in CAR T-Cell Therapy Business (2018-2023) & (US$ Million)
Table 105. Cellectis(Pipeline) Recent Development
Table 106. Allogene Therapeutics(Pipeline) Company Detail
Table 107. Allogene Therapeutics(Pipeline) Business Overview
Table 108. Allogene Therapeutics(Pipeline) CAR T-Cell Therapy Product
Table 109. Allogene Therapeutics(Pipeline) Revenue in CAR T-Cell Therapy Business (2018-2023) & (US$ Million)
Table 110. Allogene Therapeutics(Pipeline) Recent Development
Table 111. Celyad(Pipeline) Company Detail
Table 112. Celyad(Pipeline) Business Overview
Table 113. Celyad(Pipeline) CAR T-Cell Therapy Product
Table 114. Celyad(Pipeline) Revenue in CAR T-Cell Therapy Business (2018-2023) & (US$ Million)
Table 115. Celyad(Pipeline) Recent Development
Table 116. Research Programs/Design for This Report
Table 117. Key Data Information from Secondary Sources
Table 118. Key Data Information from Primary Sources
List of Figures
Figure 1. Global CAR T-Cell Therapy Market Size Comparison by Type (2023-2029) & (US$ Million)
Figure 2. Global CAR T-Cell Therapy Market Share by Type: 2022 VS 2029
Figure 3. CD19 - Targeted Features
Figure 4. BCMA - Targeted Features
Figure 5. Global CAR T-Cell Therapy Market Size Comparison by Application (2023-2029) & (US$ Million)
Figure 6. Global CAR T-Cell Therapy Market Share by Application: 2022 VS 2029
Figure 7. Lymphoma Case Studies
Figure 8. Multiple Myeloma Case Studies
Figure 9. CAR T-Cell Therapy Report Years Considered
Figure 10. Global CAR T-Cell Therapy Market Size (US$ Million), Year-over-Year: 2018-2029
Figure 11. Global CAR T-Cell Therapy Market Size, (US$ Million), 2018 VS 2022 VS 2029
Figure 12. Global CAR T-Cell Therapy Market Share by Region: 2022 VS 2029
Figure 13. Global CAR T-Cell Therapy Market Share by Players in 2022
Figure 14. Global Top CAR T-Cell Therapy Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in CAR T-Cell Therapy as of 2022)
Figure 15. The Top 10 and 5 Players Market Share by CAR T-Cell Therapy Revenue in 2022
Figure 16. North America CAR T-Cell Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 17. North America CAR T-Cell Therapy Market Share by Country (2018-2029)
Figure 18. United States CAR T-Cell Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 19. Canada CAR T-Cell Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 20. Europe CAR T-Cell Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 21. Europe CAR T-Cell Therapy Market Share by Country (2018-2029)
Figure 22. Germany CAR T-Cell Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 23. France CAR T-Cell Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 24. U.K. CAR T-Cell Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 25. Italy CAR T-Cell Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 26. Russia CAR T-Cell Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 27. Nordic Countries CAR T-Cell Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 28. Asia-Pacific CAR T-Cell Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 29. Asia-Pacific CAR T-Cell Therapy Market Share by Region (2018-2029)
Figure 30. China CAR T-Cell Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 31. Japan CAR T-Cell Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 32. South Korea CAR T-Cell Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 33. Southeast Asia CAR T-Cell Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 34. India CAR T-Cell Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 35. Australia CAR T-Cell Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 36. Latin America CAR T-Cell Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 37. Latin America CAR T-Cell Therapy Market Share by Country (2018-2029)
Figure 38. Mexico CAR T-Cell Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 39. Brazil CAR T-Cell Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 40. Middle East & Africa CAR T-Cell Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 41. Middle East & Africa CAR T-Cell Therapy Market Share by Country (2018-2029)
Figure 42. Turkey CAR T-Cell Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 43. Saudi Arabia CAR T-Cell Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 44. Novartis Revenue Growth Rate in CAR T-Cell Therapy Business (2018-2023)
Figure 45. Gilead Sciences Revenue Growth Rate in CAR T-Cell Therapy Business (2018-2023)
Figure 46. Bristol-Myers Squibb Revenue Growth Rate in CAR T-Cell Therapy Business (2018-2023)
Figure 47. J & J Revenue Growth Rate in CAR T-Cell Therapy Business (2018-2023)
Figure 48. JW Therapeutics Revenue Growth Rate in CAR T-Cell Therapy Business (2018-2023)
Figure 49. FOSUNKite Revenue Growth Rate in CAR T-Cell Therapy Business (2018-2023)
Figure 50. CARsgen Therapeutics (Pipeline) Revenue Growth Rate in CAR T-Cell Therapy Business (2018-2023)
Figure 51. Autolus Therapeutics(Pipeline) Revenue Growth Rate in CAR T-Cell Therapy Business (2018-2023)
Figure 52. Sorrento Therapeutics(Pipeline) Revenue Growth Rate in CAR T-Cell Therapy Business (2018-2023)
Figure 53. Mustang Bio(Pipeline) Revenue Growth Rate in CAR T-Cell Therapy Business (2018-2023)
Figure 54. Bluebird Bio(Pipeline) Revenue Growth Rate in CAR T-Cell Therapy Business (2018-2023)
Figure 55. Cellectis(Pipeline) Revenue Growth Rate in CAR T-Cell Therapy Business (2018-2023)
Figure 56. Allogene Therapeutics(Pipeline) Revenue Growth Rate in CAR T-Cell Therapy Business (2018-2023)
Figure 57. Celyad(Pipeline) Revenue Growth Rate in CAR T-Cell Therapy Business (2018-2023)
Figure 58. Bottom-up and Top-down Approaches for This Report
Figure 59. Data Triangulation
Figure 60. Key Executives Interviewed


*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • CD3標的薬物のグローバル市場展望 2023年-2029年：CD20+CD3ターゲット、CD3ターゲット、BCMA+CD3ターゲット、CD3+gp100ターゲット、CD3+GPRC5Dターゲット
  • 免疫細胞療法の世界市場2023年：T細胞療法、ナチュラルキラー（NK）細胞療法、その他
  • 腫瘍免疫治療の世界市場2023年：免疫チェックポイント阻害剤、サイトカイン免疫療法、がんワクチン、Car-t細胞療法、その他
  • エクソソーム療法の世界市場インサイト・予測（～2028年）
  • 細胞＆遺伝子治療用解凍装置の世界市場インサイト・予測（～2028年）
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(QYR23MA8710 )"CAR T細胞療法の世界市場2023年：CD19-対象、BCMA-対象" (英文：Global CAR T-Cell Therapy Market Research Report 2023)はQYResearch社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。